Kerry L Spear
Overview
Explore the profile of Kerry L Spear including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
158
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dedic N, Jones P, Hopkins S, Lew R, Shao L, Campbell J, et al.
J Pharmacol Exp Ther
. 2019 Aug;
371(1):1-14.
PMID: 31371483
For the past 50 years, the clinical efficacy of antipsychotic medications has relied on blockade of dopamine D receptors. Drug development of non-D compounds, seeking to avoid the limiting side...
2.
Spear K, Brown S
Drug Discov Today Technol
. 2017 Jun;
23:61-67.
PMID: 28647087
The (re)emergence of phenotypic drug discovery has been marked by a growing interest in screening campaigns that utilize phenotypic assays. The key objectives of phenotypic screens are different from those...
3.
Hopkins S, Campbell U, Heffernan M, Spear K, Jeggo R, Spanswick D, et al.
Pharmacol Res Perspect
. 2014 Dec;
1(1):e00007.
PMID: 25505561
N-methyl-d-aspartate receptor (NMDAR) activation can initiate changes in synaptic strength, evident as long-term potentiation (LTP), and is a key molecular correlate of memory formation. Inhibition of d-amino acid oxidase (DAAO)...
4.
Terry-Lorenzo R, Chun L, Brown S, Heffernan M, Fang Q, Orsini M, et al.
Biosci Rep
. 2014 Jul;
34(4).
PMID: 25001371
The NMDAR (N-methyl-D-aspartate receptor) is a central regulator of synaptic plasticity and learning and memory. hDAAO (human D-amino acid oxidase) indirectly reduces NMDAR activity by degrading the NMDAR co-agonist D-serine....
5.
Hopkins S, Heffernan M, Saraswat L, Bowen C, Melnick L, Hardy L, et al.
J Med Chem
. 2013 May;
56(9):3710-24.
PMID: 23631755
We characterized the mechanism and pharmacodynamics of five structurally distinct inhibitors of d-amino acid oxidase. All inhibitors bound the oxidized form of human enzyme with affinity slightly higher than that...
6.
Hopkins S, Zhao F, Bowen C, Fang X, Wei H, Heffernan M, et al.
J Pharmacol Exp Ther
. 2013 Mar;
345(3):502-11.
PMID: 23520265
Inhibition of d-amino acid oxidase (DAAO) activity is a potential target for the treatment of chronic pain. Here we characterized the effects of systemic administration of the DAAO inhibitor 4H-furo[3,2-b]pyrrole-5-carboxylic...
7.
Shao L, Hewitt M, Malcolm S, Wang F, Ma J, Campbell U, et al.
J Med Chem
. 2011 Jul;
54(15):5283-95.
PMID: 21739935
The present work expands the chemical space known to offer potent inhibition of the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT) and discloses novel bicyclic octahydrocyclopenta[c]pyrrole and...
8.
Shao L, Hewitt M, Wang F, Malcolm S, Ma J, Campbell J, et al.
Bioorg Med Chem Lett
. 2011 Feb;
21(5):1434-7.
PMID: 21310612
Novel chiral cyclohexylaryl amines were developed with potent reuptake inhibition against the serotonin, norepinephrine and dopamine transporters and activity at 10 and 30 mpk PO in the mouse tail suspension...
9.
Shao L, Hewitt M, Wang F, Malcolm S, Ma J, Campbell J, et al.
Bioorg Med Chem Lett
. 2011 Feb;
21(5):1438-41.
PMID: 21310609
The current work discloses a novel cyclohexylarylamine chemotype with potent inhibition of the serotonin, norepinephrine, and dopamine transporters and potential for treatment of major depressive disorder. Optimized compounds 1 (SERT,...
10.
Shao L, Ma J, Wang F, Malcolm S, Hewitt M, Campbell U, et al.
Bioorg Med Chem Lett
. 2010 Nov;
21(1):520-3.
PMID: 21095126
The present work describes a series of novel tetrahydroquinoline amines that potently inhibit the in vitro reuptake of serotonin and dopamine (dual reuptake inhibitors). The compounds are structurally related to...